((自动化翻译由路透提供，请见免责声明 ))
10月22日 - ** 药物开发商Immunic 股价盘前上涨20%至1.86美元
** 该公司称，一个独立的数据监测委员会建议继续进行一种试验性多发性硬化症药物的后期试验，不做任何改动
** 这种名为 vidofludimus calcium 的药物正在多发性硬化症患者中进行试验，多发性硬化症是一种影响中枢神经系统的慢性自身免疫性疾病。
** 委员会建议在进行中期分析--IMUX--后，该试验并非徒劳无益，应按计划继续进行。
** 公司预计这项研究将于 2026 年完成
** 截至上次收盘，股价累计上涨 3.3
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.